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Objectives: People with a history of injecting drugs have high prevalence of hepatitis C virus 
(HCV) infection, and many have opioid use disorder (OUD). Modern HCV therapies with 
improved efficacy and tolerability are available, but access is often limited for this group, who 
may be underserved for health care and face social inequity. This work develops practical steps 
to improve HCV care in this population.
Methods: Practical steps to improve HCV care in OUD populations were developed based on 
clinical experience from Spain, structured assessment of published evidence.
Results: Options for improving care at engagement/screening stages include patient education 
programs, strong provider–patient relationship, peer support, and adoption of rapid effective 
screening tools. To facilitate work up/treatment, start options include simplified work up pro-
cess, integration of HCV and OUD care, and continuous psychosocial support prior, during, 
and after HCV treatment.
Conclusion: It is important to plan on local basis to set up a joint integrated approach between 
specific drug treatment services and local points of HCV care. The elements for a specific inte-
grated program should be chosen from options identified, including education services, peer 
input, organization to make HCV screening and treatment easier by co-location of services, and 
wider access to prescribing direct-acting antiviral (DAA) therapy.
Keywords: HCV, opioid use disorder, treatment, elimination, practical recommendations
Introduction
Chronic hepatitis C virus (HCV) infection is common in people with a history of 
injecting drugs and opioid use disorder (OUD).1,2 In Europe, it is estimated that 2–3 
million individuals have a lifetime history of injecting drug use, including 1.5 million 
who have a recent history of OUD.2 HCV infection is prevalent in 14–84% of such 
groups.3 Despite high prevalence, individuals in these groups are often marginalized 
and have limited access to general health care.4 Increasing mortality/morbidity due 
to advanced liver disease defines a major public health problem among people with a 
history of injecting drugs and OUD5 and calls for enhanced access to HCV care for 
such a marginalized population.6
Direct-acting antiviral (DAA) drugs indicated for HCV treatment, with improved 
efficacy, safety profile, and tolerability, when compared with interferon-based regi-
mens, have transformed outcomes.7 DAA regimens are effective in patients receiving 
opioid agonist therapy (OAT)/opioid substitution therapy (OST) for OUD.8–10 Many 
people with a history of injecting drugs are engaged with OUD treatment services11; 
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in Europe, the proportion of engagement with OUD care 
is 40–90%.12 In Spain, an estimated 60–80,000 people are 
engaged with OUD treatment services,2 of whom 50–80% are 
infected with HCV.2,13 OUD care is often provided by social 
services, municipal authorities, or the national health ser-
vice, in different settings within each region or country.2,12,13 
These centers are separated from potential points of care 
for HCV.12 In Spain and other countries, OUD treatment is 
provided in specialist-led, often standalone offices or clinics; 
HCV specialist services are not co-located in many cases.5,12 
Local arrangements for HCV management clinical services 
are the responsibility of different parts of the health care 
system, including infectious diseases, internal medicine, and 
hepatology departments. These organizational factors limit 
the success of HCV care; social and provider-related barriers 
to HCV care are also significant.14
The objective of this work is to identify practical steps to 
improve HCV treatment in people with a history of injecting 
drugs and OUD based on clinical experience and relevant 
evidence in this evolving area.
Methods
Evidence describing interventions that may improve out-
comes in the management of HCV treatment in the context 
of OUD was collected and assessed. A structured approach 
to organize analysis was followed, applying an existing 
framework of a patient journey.2,15 This framework describes 
treatment in steps from potential initial presentation at a drug 
treatment service through steps of engagement, screening, 
work up/referral, and treatment (Figure 1).
Evidence collection
A structured search of published literature from PubMed, 
Web of Science, and Cochrane databases was completed 
using a set of predefined search terms (Table 1). The search 
was restricted to publications after 2012, when the first DAA 
medications became available. A specific additional search 
of the proceedings of recent, relevant scientific expert meet-
ings was completed to capture the most recent evidence. This 
focused on the major academic congresses of the leading 
professional societies, as identified by experts highly familiar 
with the therapy area. These included American Associa-
tion for the Study of Liver Diseases (AASLD), European 
Association for the Study of the Liver (EASL), and British 
Association for the Study of the Liver (BASL). Two reviewers 
familiar with structured literature searches and the therapy 
area assessed evidence independently and analyzed data. A 
total of 597 articles (PubMed =457, Web of Science =110, and 
Cochrane =30) and 443 abstracts (AASLD 2017=335, EASL 
2017=64, and BASL 2017=44) were screened for relevance 
(Figure 1). Studies were included if they described effective 
practice or policy interventions in improving care generally 
Figure 1 summary of the process for literature search.
Abbreviations: AAsLD, American Association for the study of Liver Diseases; BAsL, British Association for the study of the Liver; EAsL, European Association for the 
study of the Liver.
Literature databases (total N=597)
PubMed N=457
Web of Science N=110
Cochrane N=30
N=745 records after duplicates 












N= 57 studies included for analysis








Practical steps to improve Hcv in people with OUD
or for HCV specifically in people with a history of injecting 
drugs and OUD. Evidence from the literature review was 
then prioritized to identify most important practical steps 
to improve HCV care for people with OUD. Priorities were 
chosen by the authors (all with extensive clinical experience 
in HCV or OUD care) based on the opinion of potential 
impact. Interventions described in 57 studies, including 22 
full research articles, 5 reviews, 23 abstracts/posters from 
conferences, and 7 consensus recommendations were chosen 
for analysis.
Results
A series of possible options for improving OUD care at each 
stage of the patient journey were defined based on an analysis 
of evidence obtained from the literature search and analysis 
(Table 2). Studies showing effective practical interventions 
for improving HCV care in such populations are summarized 
in Table 2. Results are described according to steps on the 
patient journey.
Possible tactics to improve patient 
outcomes
Engagement
Low engagement may be addressed by education programs: 
for patients, options include brief group sessions at drug treat-
ment services including workshops, Q&A sessions, leaflets, 
videos on the basics of HCV and risk behaviors for transmis-
sion, HCV treatment pathway, right of equal access,16,17 and 
interactive digital health decision aids.18 Education sessions 
for health care professionals (HCPs) directed in primary care19 
and drug treatment services,17 and HCV awareness campaigns 
directed to the general public may be of benefit. Programs 
that actively seek patients such as pop-up and short-term 
services delivered by clinics in neighborhoods with high HCV 
prevalence are effective in promoting treatment engagement.20
Developing strong provider–patient relationships 
improves outcomes by creating an “enabling environment” 
Table 1 summary of keywords used in literature search
General terms related to Hcv care and opioid use disorder (“hepatitis c management” OR “hepatitis c treatment” OR “Hcv therapy” OR 
“treatment of chronic Hcv infection” OR “hepatitis c care” AND “People with a history of injecting drugs” OR “iDU” OR “PWiD” OR “Opioid 
Use Disorder” OR “opioid dependence” OR “opioid addiction” OR “intravenous drugs” OR “intravenous substance” OR “injecting drug” OR 
“injecting drug user” OR “heroin”).
Additional keywords specific to patient journey: “hepatitis C patient presentation” OR “hepatitis C awareness” OR “hepatitis C engagement” OR 
“Hepatitis C screening” OR “hepatitis C diagnosis” OR “hepatitis C disease staging” OR “hepatitis C fibroscan” OR “hepatitis C workup” OR 
“assess for hepatitis c treatment” OR “hepatitis c referral” OR “hepatitis c specialist” OR “complete hepatitis c treatment” OR “hepatitis c 
treatment adherence”
Abbreviation: Hcv, hepatitis c virus; iDU, injecting drug users; PWiD, people who inject drugs. 
and avoiding stigma.21,22 Peer support improves engagement 
with medical interventions23,24 and can address potential 
mistrust and fear of discrimination.25
screening
Adoption of fast and effective screening methods improves 
efficiency. Dried blood spot testing (DBST) offers antibody 
testing and RNA confirmation in one step26 and can be effec-
tively implemented in drug treatment services,27–29 alcohol 
clinics, prisons, needle equipment services,28 or via out-reach 
mobile services.30 A pretesting questionnaire-based screening 
tool helps identify people who may benefit most from testing 
in primary care.31 Community-based active case finding with 
rapid antibody oral fluid test, either by peer facilitation32 or 
by temporary clinics,20 increases screening rate in high-risk 
populations. Targeted screening at general practices in areas 
of deprivation and high prevalence of injecting drug use,33 or 
at drug treatment services, increases screening outcomes. For 
people with a history of injecting drugs who tested negative, 
it is important to offer routine testing every 12 months and 
following any high-risk injecting episode.11,34
Work up/referral
Simplified work up with access to noninvasive methods such 
as transient elastography (TE) (also known as Fibroscan) and 
serum biomarker tests accelerates the workup process and 
enables triage for immediate care35–37 implemented at drug 
treatment services, primary care, medically supervised inject-
ing centers,38 street-based outreach programs, or in prison.37 
Mobile TE further provides convenience in drug treatment 
services29 or in mobile out-reach programs for hard-to-reach 
populations of drug users, prisoners, homeless, and psychi-
atric patients30 or at primary care.39 Noninvasive serum bio-
marker tests also eliminate many of the concerns associated 
with liver biopsy.36 The aspartate aminotransferase-to-platelet 
ratio index (APRI), a calculated score predicting fibrosis,37 
is an effective prescreening tool to reduce the number of 





Table 2 summary of effective practical interventions in improving Hcv care in patients with a history of injecting drugs and OUD










Portugal Patient education 
program
A multidimensional education program including workshops, educational 
videos, leaflets, and HCP workshops improved patient knowledge and 
increased rate of patient referral to a liver specialist
17
UsA Provision of a formal Hcv education class reduced time to the initiation 
of Hcv treatment, increased patient knowledge and interest in treatment, 
and improved patient–provider communication
19
UsA interactive digital 
health decision 
aid
A tailored mobile electronic health decision aid developed to support 
methadone patients acceptable to people in treatment; viewed as useful 
for supporting engagement with HcPs
18
UsA HcP education 
program
Liver health training program for sUD clinic teams improved the 
implementation of recommended practices for Hcv screening and referral
16
Netherlands Hcv public 
awareness 
campaign
A public Hcv campaign including radio and newspaper ads and 
information material distributed at public places increased number of anti-
Hcv tests 1.36-fold in a 3-month period. Addition of a support program 




371 previously undiagnosed patients have been identified and 43% linked 







London health care providers adopted a “negotiated flexibility” approach 
to appointments, eligibility, substance use, and phlebotomy to facilitate the 
trust and engagement of PWiD
72
Australia Peer support 
service
Peer support service improved engagement, helped to build trusting 
relationships, and provided instrumental support for clients to access 
Hcv treatment. Peer workers may also contribute to more effective 
deployment of health resources by preparing clients for clinical 
engagement with Hcv health workers
23
Australia integrated peer 
support worker 
model
in an Ost clinic with integrated peer support model, peer support 
workers facilitated broader discussion about Hcv treatment, education, 
and support. this approach allows nurses to focus on assessment and 









scotland integrated DBst DBst was effectively carried out at drug treatment and needle exchange 
services following appropriate training of staff. A total of 324 “hard to 
reach” patients tested Hcv antibody positive within a 2-year period, 249 





interim data showed high treatment uptake compared to hospital-based 
settings and suggested that Hcv care can be effectively provided through 
a community-based model
77
France DBst via out-
reach mobile 
services
Hepatitis Mobile team carried out 944 dry DBst for hard-to-reach 




based Hcv risk 
screening tool
The first level-screening tool assessed risk factors significantly associated 
with Hcv infection. integration of such a tool into primary care practice 
can promote early detection
31
UK community-
based active case 
finding by peer 
facilitation
379 homeless people were screened over a 1-year period. A total of 68 






test uptake and case yield were approximately 3 and 10 times higher in 







implementation of a multifaceted screening program at an sUD clinic 
increased patient referral rates to specialist care
78
Work Australia APRi score APRi score may be used as a simple noninvasive biomarker for cirrhosis 
with reasonable predictive accuracy
37
(Continued)
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Australia tE PWID viewed TE as a highly acceptable diagnostic method; 89% of patients 







Portable Fibroscan was implemented as a part of an Hcv outreach service 
in a community addiction clinics. Median time from referral to treatment 
initiation was 32 weeks
39
canada Patient survey survey of patient’s needs and preferences showed no single preferred 
approach for different aspects of care; a multipronged and flexible 
approach at all stages of the patient pathway is most likely to be successful
40
UsA Peer mentors Patients receiving usual care with the addition of peer mentors had a 
significantly higher rate of HCV treatment initiation when compared to 
usual care alone
41
Portugal HcP education 
program
A multidimensional health education program for patients and HcP at 
seven drug treatment centers significantly increased rates of patient 

















PcPs were trained to treat Hcv through video conferencing, case-based 
learning, and mentoring. They were generally confident treating patients, 






implementation of an onsite multidisciplinary Hcv team and noninvasive 
fibrosis assessment at a drug treatment center increased HCV 
assessments and treatment uptake when compared with previous model 
of hospital referral
44
UK 105 patients were recruited through needle exchange centers over 
42 months; 89 patients received treatment in a needle exchange; 74 





the highly successful JailFree-c program involved universal screening of 
inmates and integrated Hcv treatment. A total of 821 inmates tested, 81 
identified as viremic, and 64 received treatment. SVR rates were similar to 
those in community
46
UsA Hcv treatment 
as a part of 
integrated OUD 
treatment plan
Hcv care delivered under-one-roof as a part of an OAt program 
achieved high rates of SVR12 among 136 participants (93%)
47
UsA HCV care within an office-based OST clinic was successfully set up; 95% of 
patients achieved early viral response at 4 weeks and svR was achieved by 
100% of patients who completed treatment
48
UK Predictive modeling and sensitivity analyses used to project future Hcv 
population suggested that combining Hcv antiviral treatment with OAt 
and needle equipment programs could have chronic Hcv prevalence over 
10 years
49
Ukraine A community-involved model providing integrated Hcv treatment and 
drug treatment services has successfully enrolled over 1,200 patients for 





Embedding of addiction specialists in an Hcv clinic to provide integration 
between methadone clinic and hepatitis clinic sites improved patient’s 




training program allowed 700 patients to be treated at clinics not 
previously authorized to provide care for Hcv demonstrating the power 
in this approach to facilitate up-scaling of effective Hcv treatment
52
Australia DAA prescribing 
by PcP
innovative teleconferencing approach allowed Hcv care to be effectively 
provided by PcPs and may facilitate treatment in populations engaged with 
other treatment services
53




A nurse-led model of Hcv care provision in Ost clinics was implemented 
and has reviewed over 300 patients with viral hepatitis with therapy 























community-based nurse-led hepatitis service produced reasonable rates of 
fibrosis staging (72%) and treatment initiation (20%) for PWID. A total of 
70% of genotype 1 patients and 54% of genotype 3 patients achieved SVR
55
UsA DAA prescribing 
in primary care
Access to Hcv treatment at a primary care clinic under the supervision 
of a hepatologist resulted in high screening rates and cure rates similar to 
those reported elsewhere
56
Australia DAA prescribing 
in prisons
APRi score was used for patient evaluation and DAA therapy prescribed 
to relevant patients to provide successful care in a resource-limited prison 
setting
37
UsA DAA prescribing 
at pharmacist-led 
clinics
Hcv treatment including DAA therapy provided through pharmacist-
managed clinics recorded similar svR rates to those achieved in primary 
care. Pharmacists can be used to help widen access to effective care for 
Hcv
58
switzerland Digital platform 
for clinical 
decision making
smartphone application for access to national treatment guidelines 
provided faster access to more detailed and specific information to 
facilitate clinical decision making when compared with traditional web-
based publications
59
UsA teleconsultation Patients approved assessment by two-way video conferencing, and there 








A community-based highly supportive model (which included counseling, 
case management, peer workers, and other services) promoted high levels 





4-Week treatment regime with LDv/sOF/RBv ± PEG2 was highly effective 





Patients with injecting drug use were significantly more likely to complete 
an HBV vaccination series if they received a 30 AUD financial incentive 





A multidisciplinary care program with enhanced long-term follow-up 
achieved high svR rates and low rates of recurrent viremia following 
therapy
65
Greece A model developed to simulate Hcv transmission among PWiD 
demonstrated the need for scaled-up harm reduction interventions to 
maintain reductions in Hcv prevalence and prevent any resurgence
66
Abbreviations: APRi, aspartate aminotransferase-to-platelet ratio index; AUD, Australian dollars; DBst, dried blood spot testing; GP, general physician; HcPs, health care 
professionals; HBv, hepatitis B virus; Hcv, hepatitis c virus; iDU, injecting drug users; LDv/sOF/RBv, Ledipasvir/ sofobuvir/ Ribavirin; NHs, National Health system; OAt, 
opioid agonist therapy; Ost, opioid substitution therapy; OUD, opioid use disorder; PcPs, primary care physicians; PWiD, people who inject drugs; svR, sustained virologic 
response; sUD, substance use disorder; tE, transient elastography.
Table 2 (Continued)
patients requiring Fibroscan.37 Logistic support such as 
tailored flexible scheduling facilitates work up completion.40
A tailored approach with different options for engagement 
is most likely to be successful.40 Referral processes can be 
facilitated by education for HCP at drug treatment services17 
and primary care;19 support from peer mentors facilitates 
linkage to start HCV treatment.41
treatment
A single-location clinic with access to a multidisciplinary team 
is effective in facilitating the progression from patient identi-
fication to HCV treatment.20,42 Integrated HCV treatment can 
be provided at primary care,39,43 drug treatment services,39,44 
needle equipment services,45 or prison.46 It can be as a part of 
a traditional integrated treatment plan for OUD,47,48 or as a part 
of a combined program of integrated drug treatment, HCV, and 
needle equipment program,49,50 or for people who are actively 
injecting and not receiving integrated treatment for OUD.45 
Addiction specialists based in HCV clinics51 or mobile teams 
for screening, diagnosis, and treatment may address underserved 
populations.30 Wider prescribing options for DAA including 
primary care physicians (PCPs) increases treatment access;43,52,53 
treatment can be delivered in nurse-led drug treatment ser-
vices,39,54 primary care,39,55,56 prison,57 or pharmacist-led clinics.58
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Smartphone or desktop digital platforms assist clinical 
decision making and facilitate treatment initiation.59 Tele-
consultation is effective in overcoming physical barriers of 
having to meet with the HCV specialists.60
Adherence to treatment can be facilitated with psychosocial 
support, such as continuous counseling,61 case management 
services, actively screening for psychiatric comorbidities with 
referral to mental health providers including co-located special-
ists at HCV clinics and referral to peer-support groups with OUD 
care and buddy systems. Shorter treatment duration tailored to 
the population of injecting drug users may be effective.62
Peer-led models combined with multidisciplinary care 
lead to improved knowledge, treatment uptake, and service 
provision.23,25 Contingency management, including monetary 
incentives, is effective in improving adherence to hepatitis B 
virus vaccination63 and promotes HCV treatment initiation41 
among people with a history of injecting drugs. Developing 
or implementing existing national strategies, action plans, 
and guidelines for HCV treatment in people with a history 
of injecting drugs helps establish best practices.64
Re-infection risk is limited by long-term follow-up with 
access to multidisciplinary care and harm reduction services 
after HCV treatment.65–67 Regular HCV testing after the treat-
ment and analysis of risk factors for re-infection is helpful for 
early engagement for potential interventions.5,11,68,69
Discussion
DAA regimens offer the possibility of cure for HCV. People 
with a history of injecting drugs and OUD represent a major 
group requiring HCV treatment but find it hard to access 
care. It is the opinion of the authors that it is essential, now, 
to address limits to therapy access if HCV treatment uptake 
is to be available to all and eradication of the infection is to 
be achieved. Many citizens with great need for HCV therapy 
cannot navigate pathways to get the HCV care they need. Law, 
policy, and guidelines in many European countries defines the 
equality of access to health care for all citizens and increas-
ingly for HCV treatment – it is the reality that despite this 
and if action is not taken, many with the greatest needs will 
not be able to access proven treatment for a serious condition.
This structured assessment identifies practical steps from 
published evidence, which can improve HCV care in people 
with a history of OUD. Recommendations for practical steps 
to improve care are shown in Figure 2 and summarized here:
1. Provide peer-led education for patients with OUD includ-
ing updates on HCV and liver health, DAA therapy, right 
of equal access to therapy, and how to navigate treatment 
pathways.17,18,70
2. Develop “enabling” provider–patient relationships22,71,72 
to support HCV treatment pathway navigation.19,73
Figure 2 Practical recommendations for best practices of Hcv treatment for people with OUD.
Note: A patient journey model, with steps of engagement, screening, workup/referral, and treatment, is used to structure practical recommendations.
















Engagement Work up/referral Treatment Screening 
Practice
• Provide education for OUD 
patients on HCV and liver 
health basics, DAA therapy, 
right to equal access, and how 
to navigate treatment pathway
• Adopt “one stop” tests of fast 
and easy screening, inform work 
up and treatment choices
• Make treatment easy with wide 
options for access to HCV care.
• Develop “enabling” provider–
patient relationships; HCP active 
referral to support treatment 
pathway navigation
• Use supportive networks (eg 
peer–support, buddy systems, 
counselling) to encourage 
engagement
• Offer ongoing screening based 
on risk onsite or “mobile” 
outreach
• Simplify work up; suit patients’
needs/encourage attendance
• Standardize referral procedure 
based on understanding of 
starting points and HCV therapy
location options locally 
• Provision of integrated HCV 
care, set up joint local working 
teams with HCP and 
administration from OUD, HCV, 
and primary care services
• Consider wider prescription 
rights for PCP; care delivery by 
nurses, pharmacists in primary 
care, OUD centers, and prison
• Ensure access to harm reduction to prevent reinfection; provide regular testing after treatment for early engagement of potential 
interventions
• Ensure local guidelines are clear and promote best practice; collect data to measure performance, indicate improvement potential, and 
share service provision locations
Patient decides to find HCV
status and get treatment options
HCV antibody test completed,
RNA confirmed; results discussed
Liver status assessed; patient plans
treatment with a HCV specialist
Patient starts, completes treatment
under guidance; prevent reinfection
• Consider the option of contingency management to promote engagement and adherence of treatment regimen 





3. Standardize HCV referral procedure based on the under-
standing of starting points and treatment location options 
and use supportive networks (eg, peer support, buddy 
systems, counseling) to encourage engagement.23–25
4. Provide “one stop” fast and easy screening services, pro-
viding all necessary diagnostic information.5,27–29 Offer 
ongoing screening based on risk onsite or with “mobile” 
outreach.11,20,30,33,34
5. Simplify work up to encourage attendance; develop local 
capability with noninvasive liver assessment within drug 
treatment clinics.29,36,38,70
6. Make treatment easy with wide options for access 
to HCV care services. Implement wider prescription 
rights for PCP43,52 and care delivery by nurses and phar-
macists in primary care, drug treatment services, and 
prison.39,43,54,57,58
7. Provide integrated HCV care,5,11,39,42,47,51,74 set up joint local 
working teams of HCP and administration from OUD, 
HCV, and PCP services focused on HCV treatment.
8. Review service results jointly to set standards of care 
and inform service development including “all under one 
roof ” models and develop local guidelines to promote 
best practice.64
9. Collect data to measure performance, indicate improve-
ment potential, share results among local service provid-
ers and locations.
10. Ensure continuing access to harm reduction to prevent 
reinfection; provide regular testing after treatment for the 
early engagement of potential interventions.5,11,66–68,75
This recommendation is based on the clinical experience 
of clinicians with highly relevant long-term experience and 
interpretation of a review of current evidence. Evidence 
is collated from available published sources; this work is 
limited in this respect – in this evolving field, it is important 
to reconsider this work in the light of new evidence, in the 
future. Priorities are set based on clinical experience in Spain 
and observation of international practices. It is noted that the 
challenges for HCV and OUD treatment services are common 
in other countries12 and that the wide range of models of care 
and experience in managing HCV in Spain and its regions may 
be representative of the approach in many other countries. This 
work identifies practical steps based on clinical factors; there 
are other social and provider-related factors outside the scope 
of this article that are important to address in this population.
Conclusion
People with a history of injecting drugs engaged with OUD 
care services often face considerable barriers for HCV care. 
The recommendations advocated here for practical steps to 
improve care should be considered by all aiming to improve 
outcomes for marginalized populations who may find it difficult 
to access treatment for HCV.
Abbreviations
APRI, aspartate aminotransferase-to-platelet ratio index; 
DAA, direct-acting antiviral; DBST, dried blood spot testing; 
HCPs, health care professionals; HCV, hepatitis C virus; OAT, 
opioid agonist therapy; OST, opioid substitution therapy; 
OUD, opioid use disorder; PCPs, primary care physicians; 
TE, transient elastography; IDU, injecting drug users; PWID, 
people who inject drugs. 
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